- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * SHEMA SUZANNE M	2. Issuer Name and Ticker or Trading Symbol ONYX PHARMACEUTICALS INC [ ONXX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                      _____ 10% Owner __ X __ Officer (give title below)      _____ Other (specify below) EVP, GC and Corp. Secretary
(Last)          (First)          (Middle) C/O ONYX PHARMACEUTICALS, INC., 249 E. GRAND AVE.	3. Date of Earliest Transaction (MM/DD/YYYY) 12/10/2012
(Street) SOUTH SAN FRANCISCO, CA 94080 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/10/2012		M		1345	A	$32.07	37492	D
Common Stock	12/10/2012		M		656	A	$30.28	38148	D
Common Stock	12/10/2012		M		3208	A	$35.18	41356	D
Common Stock	12/10/2012		M		2100	A	$37.68	43456	D
Common Stock	12/10/2012		M		4775	A	$37.68	48231	D
Common Stock	12/10/2012		S		14398   (1)	D	$77.68   (5)	33833	D

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$32.07	12/10/2012		M			1345	(2)	8/31/2019	Common Stock	1345	$0.00	23531	D
Stock Option (Right to Buy)	$30.28	12/10/2012		M			656	(3)	3/31/2020	Common Stock	656	$0.00	10500	D
Stock Option (Right to Buy)	$35.18	12/10/2012		M			3208	(2)	3/31/2021	Common Stock	3208	$0.00	22459	D
Stock Option (Right to Buy)	$37.68	12/10/2012		M			2100	(4)	3/29/2022	Common Stock	2100	$0.00	23800	D
Stock Option (Right to Buy)	$37.68	12/10/2012		M			4775	(3)	3/29/2022	Common Stock	4775	$0.00	33425	D

Explanation of Responses:
( 1)	Shares sold pursuant to a 10b5-1 plan.
( 2)	25% of the shares subject to the option become exercisable one year following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 36 months for a total vesting schedule of 48 months.
( 3)	12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.
( 4)	The shares vest monthly from the date of grant at a rate of 1/48th per month.
( 5)	The shares were sold at prices ranging from $77.3201 to $78.01. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
SHEMA SUZANNE M C/O ONYX PHARMACEUTICALS, INC. 249 E. GRAND AVE. SOUTH SAN FRANCISCO, CA 94080			EVP, GC and Corp. Secretary

Signatures
/s/ Warren DeSouza, Attorney-in-fact		12/11/2012
** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.